The mrna therapeutics market in the UK is expected to reach a projected revenue of US$ 1,883.7 million by 2030. A compound annual growth rate of 16.4% is expected of the UK mrna therapeutics market from 2024 to 2030.
The UK mrna therapeutics market generated a revenue of USD 651.1 million in 2023 and is expected to reach USD 1,883.7 million by 2030.
The UK market is expected to grow at a CAGR of 16.4% from 2024 to 2030.
In terms of segment, infectious diseases was the largest revenue generating application in 2023.
Infectious Diseases is the most lucrative application segment registering the fastest growth during the forecast period.
Mrna therapeutics market data book summary
Market revenue in 2023
USD 651.1 million
Market revenue in 2030
USD 1,883.7 million
Growth rate
16.4% (CAGR from 2023 to 2030)
Largest segment
Infectious diseases
Fastest growing segment
Infectious Diseases
Historical data
2021 - 2022
Base year
2023
Forecast period
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Infectious Diseases
Key market players worldwide
Moderna Inc, BioNTech SE ADR, CureVac NV Ordinary Shares, Arcturus Therapeutics Holdings Inc, Sanofi SA, GSK PLC, Pfizer Inc, AstraZeneca PLC, Argos Therapeutics, ETHRIS
Other key industry trends
In terms of revenue, UK accounted for 5.5% of the global mrna therapeutics market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Europe, Germany mrna therapeutics market is projected to lead the regional market in terms of revenue in 2030.
UK is the fastest growing regional market in Europe and is projected to reach USD 1,883.7 million by 2030.
Growing government deals with companies active in the mRNA space are being signed within the country to manage the pandemic. For instance, in January 2023, the UK government announced a strategic partnership with BioN Tech to set up new R&D centers in the UK to deliver 10,000 personalized mRNA therapies to patients before 2030.
Similarly, in December 2022, the UK government and Moderna signed a deal to construct an mRNA facility in the UK. The facility is anticipated to offer access to locally produced future mRNA vaccine portfolio against respiratory viruses in the UK. Such initiatives in the region by industry players in the UK are expected to drive the mRNA therapeutics market during the forecast period.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to MRNA Therapeutics Market Outlook will help companies and investors design strategic landscapes.
Infectious Diseases was the largest segment with a revenue share of 100.0% in 2023.
Horizon Databook has segmented the U.K. mrna therapeutics market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
Growing government deals with companies active in the mRNA space are being signed within the country to manage the pandemic. For instance, in January 2023, the UK government announced a strategic partnership with BioN Tech to set up new R&D centers in the UK to deliver 10,000 personalized mRNA therapies to patients before 2030.
Similarly, in December 2022, the UK government and Moderna signed a deal to construct an mRNA facility in the UK. The facility is anticipated to offer access to locally produced future mRNA vaccine portfolio against respiratory viruses in the UK. Such initiatives in the region by industry players in the UK are expected to drive the mRNA therapeutics market during the forecast period.
U.K. Mrna Therapeutics Market Application Outlook (Revenue, USD Million , 2021-2030)
Infectious Diseases
Oncology
Rare Genetic Diseases
Respiratory Diseases
Others
U.K. Mrna Therapeutics Market Type Outlook (Revenue, USD Million , 2021-2030)
Prophylactic
Therapeutic
U.K. Mrna Therapeutics Market End Use Outlook (Revenue, USD Million , 2021-2030)
Hospitals & Clinics
Research Organizations
Others
Reasons to subscribe to MRNA Therapeutics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of MRNA Therapeutics Market Outlook databook
Our clientele includes a mix of MRNA Therapeutics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. MRNA Therapeutics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. MRNA Therapeutics Market Outlook from 2021 to 2030, including revenue numbers, major trends, and company profiles.